Table 1 Baseline characteristics and laboratory tests of 349 patients
Total (n = 349) | Survivors (n = 297) | Death (n = 52) | P | ||
|---|---|---|---|---|---|
Gender (Male,%) | 173(49.60%) | 137(46.10%) | 36(69.2%) | 0.002 | |
Age (years), n = 349 | 62.00(21.00–69.00) | 60.00(50.00–67.00) | 69.00(63.25–75.50) | < 0.001 | |
Hospitalization days (days), n = 349 | 12.00(7.32–17.00) | 11.00(7.00–16.00) | 14.00(9.00–23.75) | 0.006 | |
Initial D-Dimer (mg/L), n = 349 | 0.39(0.17–0.95) | 0.35(0.15–0.62) | 1.81(0.52–9.34) | < 0.001 | |
FIB(g/L),n = 345 | 3.83(3.13–4.79) | 3.83(3.22–4.82) | 3.92(2.89–4.71) | 0.349 | |
APTT(s),n = 347 | 34.80(32.40–38.50) | 34.90(32.40–38.20) | 34.60(32.08–41.48) | 0.488 | |
PT(s),n = 347 | 13.00(12.40–13.90) | 12.80(12.40–13.50) | 14.30(12.93–15.80) | < 0.001 | |
Initial NLR, n = 349 | 3.33(1.94–9.42) | 2.88(1.79–6.74) | 14.96(8.52–26.58) | < 0.001 | |
CRP (mg/L),n = 276 | 18.59(0.99–61.84) | 12.31(0.84–47.08) | 65.45(25.81–98.90) | < 0.001 | |
PCT (ng/ml), n = 250 | 0.04(0.04–0.05) | 0.04(0.04–0.04) | 0.12(0.04–0.39) | < 0.001 | |
TNI (ng/ml),n = 215 | 0.03(0.01–0.03) | 0.01(0.01–0.03) | 0.03(0.03–0.12) | < 0.001 | |
NT-proBNP (pg/ml),n = 240 | 102.00(23.00–442.25) | 64.00(16.50–249.00) | 709.00(322.00–1282.00) | < 0.001 | |
Comorbidity(n,%) | Respiratory failure | 44(12.60%) | 17(5.70%) | 27(51.90%) | < 0.001 |
ARDS | 35(10.00%) | 11(3.70%) | 24(46.20%) | < 0.001 | |
Heart failure | 16(4.60%) | 5(1.70%) | 11(21.20%) | < 0.001 | |
AKI | 14(4.00%) | 1(0.30%) | 13(25.00%) | < 0.001 | |
Hypertension | 103(29.50%) | 73(24.60%) | 30(57.70%) | < 0.001 | |
Diabetes mellitus | 57(16.30%) | 41(13.80%) | 16(30.80%) | 0.004 | |
Hypoproteinemia | 71(20.30%) | 53(17.80%) | 18(34.60%) | 0.009 | |